Condition
Cadmium Exceeds the Standard
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06572566CompletedPrimary
Study on Neuropsychiatric Behavior in Cadmium-exposed People
NCT07057414Phase 2RecruitingPrimary
The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels
NCT06199349Phase 1CompletedPrimary
Safety Study of GMDTC Injection in Participants With Excessive Cadmium
Showing all 3 trials